Microglial cells form a context-dependent network of brain immunoeffector cells. Despite their indispensable roles, unresolved questions exist around biomarker discovery relevant to their cellular localization, self-renewing potential, and brain developmental dynamics. To resolve the existent gap in the annotation of candidate biomarkers, we conducted a meta-analysis of brain cells using available high-throughput data sets for deciphering microglia-specific expression profiles. We have identified 3,290 significant genes specific to microglia and further selected the top 20 dysregulated genes on the basis of p-value and log2FC. To this list, we added 7 known microglia-specific markers making the candidate list comprising 27 genes for further downstream analyses. Next, we established a connectome of these potential markers with their putative protein partners, which demonstrated strong associations of upregulated genes like Dedicator of cytokinesis 2 (DOCK2) with early/mature microglial markers such as Sphingosine kinase 1 (SPHK1), CD68, and CD45. To elucidate their respective brain anatomical location, we deconvoluted the BrainSpan Atlas expression data. This analysis showed high expression of the majority of candidate genes in microglia-dense regions (Amygdala, Hippocampus, Striatum) in the postnatal brain. Furthermore, to decipher their localized expression across brain ages, we constructed a developmental dynamics map (DDM) comprising extensive gene expression profiles throughout prenatal to postnatal stages, which resulted in the discovery of novel microglia-specific gene signatures. One of the interesting readout from DDM is that all the microglia-dense regions exhibit dynamic regulation of few genes at 37 post conception week (pcw), the transition period between pre-and postnatal stages. To validate these findings and correlate them as potential biomarkers, we analyzed the expression of corresponding proteins in hESC-derived human micr oglia precursors. The cultured microglial precursors showed expression of Pentraxin 3 (PTX3) and SPHK1 as well as several known markers like CD68, Allograft inflammatory factor 1 (AIF1/IBA1). In summary, this study has furnished critical insights into microglia dynamics across human brain ages and cataloged potential transcriptomic fingerprints that can be further exploited for designing novel neurotherapeutics.
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The complex human brain is composed of neurons embedded in a framework of glial cells (astrocytes, oligodendrocytes, and microglia) and blood vessels. Microglial cells, the third and highly motile type of glial cell populating the brain were first identified and simultaneously reported by F. Robertson and F. Nissl, who first gave them the name "Staebchenzellen" based on their rod-like nuclei shape (1, 2) . Later, these cells were renamed as "microglia" by Pio del Rio-Hortega, who further characterized and delimited them from other glial types (3) . It is noteworthy that the pri mary role of microglia is to dynamically monitor CNS-invading threats.
Studies have proven that microglia play critical functions like maintenance of neuronal development by continuous patro lling of active neurons, scavenging dead neurons and dendritic spine pruning under normal physiological conditions (4) (5) (6) . Abnormal microglial activities can either under-prune or over-trim the dendritic spines leading to progressive neurodevelopmental defects (5) . Besides this, these brain scavengers can play multidimensional roles in maintaining brain homeostasis. One of the newly discovered roles suggests that microglia regulates the number of healthy neural precursor cells (NPCs) in adult brain (7, 8) . First, microglia control the number of NPCs by selectively colonizing near proliferative NPC zones and phagocytizing the neural precursors in utero, and second, the microglial activity gets regulated in the brain by NPC-derived chemokines, such as VEGF, as shown by increased microglial density surrounding NPC pool (9, 10) . Notably, this NPC-microglia crosstalk is most active during neuroinflammation, as microglia is one of the primary innate immunoeffector cells (10, 11) . They usually accumulate around degenerating neurons, leading to the obvious misconception of causing detrimental effects. Albeit monumental efforts made toward understanding microglia dynamics in the developing brain, knowledge regarding their cellular localization, self-renewal/expansion property, and other stage-specific roles is still in its infancy. Origin and continual existence of microglia throughout human brain span are being currently investigated. Interestingly, microglial ontogeny describes three lines of opinions. This includes its emergence either during the embryonic day (E7.0-E10.5) from yolk sac (YS) (12) (13) (14) (15) or their infiltration during diseased conditions from bone-marrow (16) . There is also a third view which suggests that microglia is of neuroectodermal origin, derived either from glioblasts or from the germinal matrix (17) . In a recent study, Tay et al. established an in vivo fate mapping system and studied proliferation of microglia in the healthy and diseased brain which demonstrated a context-dependent growth pattern of microglia under normal physiological conditions and selective clonal expansion during disease states (18) .
The burning questions of the hour deal with life-long inhabitation and maintenance of microglia in the human brain. Answers to these will shed light underlying disease onset and manifestations in several neurological diseases including Alzheimer's disease and Parkinson's disease (AD and PD). One of the challenges in microglial biology is to track their expression and activity throughout the brain development (fetal to adult and aged brain stages). Till date, hardly any study exists that has shed light on in silico or in vivo tracking of the microglial population (19) . Specifically, microglial age and variance over brain regions can be the guidance cue to understanding onset and progression of neurodegenerative disorders (20) (21) (22) (23) . To track microglia-specific biomarker expression, their localization, and generation of a regulatory dynamic map, this study presents an integrated meta-analysis approach wherein, we analyzed the differentially expressed microglia-specific gene subsets using available data repositories. This led to a unique catalog of genes (27) which are dynamically/consistently expressed in the microglial population during different stages of brain development. For the first time, we have employed a novel strategy for in silico monitoring of microglial gene signatures to decipher their developmental dynamics map (DDM). Interestingly, protein-protein interaction network analysis revealed six different protein clusters, which exposed primary interacting partners like Tissue factor (coagulation) protein family, Retinoid X receptor gamma signaling linked MGST protein family, ATP-dependent protein family, and hippocampal BMP signaling molecules like BMP4. Furthermore, region specificity of the above candidates was evaluated using Allen Brain Atlas's (ABA) BrainSpan which revealed localized expression of several genes in microglia-centric regions. Finally, to validate the emergence of early/mature microglial signatures in vitro, we induced hESC-derived microglial differentiation using an in-house protocol. In conclusion, the study has validated the expression of stage-specific markers as well as presented an updated catalog of potential age-specific microglial biomarkers, which can be used as future prognostic biomarkers. The overall strategy adopted for in silico analyses has been compiled (Figure 1 ).
MaTerials anD MeThODs literature survey
We utilized repositories including NCBI Pubmed and HighWirePress to understand the prior literature linked to microglia biology. Other high-throughput data repositories like NCBI's Gene Expression Omnibus (GEO) and Sequence Read Archive (SRA) were scanned for biological sequence data specific to transcriptomics of human microglia.
high-Throughput Data analysis
First, using available RNA-sequencing data set linked to microglia transcriptomics (24), we delineated the brain cell-type specific expression in accordance with different brain cell types namely, microglia, astrocytes, endothelium, oligodendrocytes, and neurons. Specifically, we evaluated the differential expression between Rest of the Brain Cells comprising astrocytes, endothelial cells, oligodendrocytes and neurons (ROBC), and microglial cell type. Log2FoldChange (FC) values threshold of ±1.5 was considered with a p-value significance of <0.05. This formed our primary data set comprising microglia cell type-specific genes. Our secondary data set was utilized to gauge the correlation of differential expression between brain cell types and differential expression of induced pluripotent stem cells (iPSCs) versus derived microglia. This data series deposited in GEO database contains human microglia-specific microarray Affy HuGene-2_0-st data (GSE78115) (25) . Specifically, we considered the 12 samples (3 replicates each) derived from 2 different cell lines NCRM-5 and iNC-01 of iPSC origin. Using OLIGO package of R Biocon ductor, we performed data analysis (including data normalization) to assess the differential expression pattern specific to human microglia with respect to iPSCs. The OLIGO package is freely available through Bioconductor website (26) . Differential expression cutoff of ±1.5 log2FC and p-value <0.05 was considered significant in all cases. The differentially expressed genes from both primary and secondary human microglia sample sets were combined to ensure minimal data loss. This integration yielded a common pool of microglial specific genes (3,290), which was further used for downstream analyses. Pearson correlation coefficient was calculated for the integrated gene list (3,290) using R. We further analyzed the expression patterning between the primary and secondary data sets using the top 20 (out of 3,290) up and downregulated genes, which were shortlisted on the basis of p-value and log2FC values below 0.01 and above ±5.0, respectively. To this list, we also added a list of seven known biomarker genes specific to microglia for understanding their development expression dynamics. Taken together, the total list used for brain age and region-specific dynamics consisted of 27 genes.
Protein classification and Pathway analysis
We utilized Protein ANalysis THrough Evolutionary Relationships classification system and mapped the total differentially expressed list of 3,290 genes to various protein classes for elucidating their functional significance (27) . For pathway analysis, we inputted the same gene list to Consensus PathDB-human to identify their key associative pathways (28 
Protein-Protein interaction network analysis
The differentially expressed gene list (3290) was mapped to STRING for whole proteome network analysis. Furthermore, the shortlisted microglia-specific gene list (27) was also analyzed for protein partner associations using STRING (29) . Primarily, using all the top upregulated and downregulated protein clusters, a single protein-protein network was constructed. A stringent cutoff of 0.7 for edge/interaction score was considered for building the primary protein-protein interaction network without clustering and no more than 20 primary interactor proteins. This combined confidence score is calculated on the basis of various parameters including phylogenetic co-occurrence, gene fusion, homology, co-expression, experimentally determined interaction, and neighborhood on any chromosome. The graph was primarily constructed according to interaction/edge score while specifying the source and target nodes. All networks were visualized using Cytoscape 3.4.0 (30).
Brain region expression Mapping
The Allen Brain Atlas contains an extensive catalog of human brain expression data (Microarray and RNA-Seq) with region specificity (31, 32) . We collected the raw data of the developmental transcriptome from Allen Brain Atlas and segregated the data into different ages from prenatal to postnatal (adult) brain (31) . Here, we mapped the top gene set of 27 genes onto all the prenatal and postnatal brain regions, with a special emphasis on human microglia-enriched regions like Hippocampus, Striatum, and Amygdala. Other than these genes, we also show the expression of known microglial marker genes like TMEM119, P2RY12, Phospholipase D4 (PLD4), AIF1, PTPRC1, Sphingosine kinase 1 (SPHK1), PTX3, and G protein-coupled receptor 34 (GPR34).
age-Wise Dynamics
To assess the microglia dynamics throughout the age (pre-and postnatal) of a human being, we utilized the human developmental transcriptome data (BrainSpan) deposited in the Allen Brain database (33, 34) . Replicate samples for each developmental stage (prenatal or postnatal) were considered for analysis. The age groups ranged from prenatal stages, including 14th postconception week (pcw), 22 pcw to 40 years of age. Specifically, for each microglia-enriched region of the brain (hippocampus, striatum, and amygdala), we constructed individual graphs for age-wise DDM of potential and known microglia-specific markers which included shortlisted gene set of 27, containing 20 (p-value < 0.01, log2FC > ±5.0) and 7 known markers. Following this, correlation analysis was performed using the same gene list as input to find correlations among the human ages spanning prenatal stages like 12 pcw, 37 pcw to postnatal stages, such as 1, 15-19, and 40 years of age. Pearson correlation matrices or correlograms were constructed and visualized using the Corrplot package of R Bioconductor suite. All graphs have been made using RStudio 1.0.153 (35) .
culturing of human embryonic stem cells (h9)
Human embryonic stem cells (h9-hESC, NIH approved) were obtained from human embryonic stem cell core, Baylor College of Medicine. H9 clones were propagated based on feeder-free culture system, using human ESC-qualified Matrix, BD Matrigel (BD Biosciences, San Jose, CA, USA), and grown in mTeSR-1 complete media supplements (Stemcell Technologies, Vancouver, BC, Canada) at 37°C and 5% CO2. Clones were maintained and expanded according to manufacturer's protocol, in accordance with NIH guidelines. Complete media was changed every day and cells were sub-cultured using Dispase (Stemcell Techno logies, Vancouver, BC, Canada) every 5-6 days. During each stage of subculture, uniform H9 colonies were collected without any visible differentiation.
embryonic Body (eB) Formation
To induce the formation of EBs or neuroectodermal spheres, the H9 colonies with 70% confluency were used. To achieve neural induction, H9 colonies were incubated in neural induction me-dium [NIM; DMEM/F12: Neurobasal (1:1), 2% B27, 1% N2 (Invitrogen)] for almost 24 h and dissociated into small clumps by manual scraping. Small clumps were further grown as suspension culture with NIM in non-coated bacterial Petri dishes for a period of 4 days as exactly described by Cho et al. (36) . 50% of the media were replaced in each of the EB-containing Petri dishes at a timely interval of 48 h.
Microglial Differentiation and generation of Microglia Precursors From hesc
To induce microglial differentiation in culture from H9 derived EBs and obtain human microglial precursors in vitro, we used an in-house standardized protocol (unpublished), modified based on an earlier established protocol (37) . In brief, the whole process goes through a long-term culture (approximately 8 weeks) covering four major steps, (i) formation of hESC (H9) derived EBs, (ii) neuroectodermal lineage commitment, (iii) microglial diffe rentiation, and (iv) formation of induced microglia precursors (iMPs), as suggested in the previous article by Beutner et al. (37) . We have used stage-specific conditioned media supplements as suggested by Beutner et al., including differentiation media (DIFF), Insulin/Transferrin/Selenite/Fibronectin media (ITSFn) and N2 Media. However, we have introduced several modifications during the stage-specific progression of microglial differentiation. These include the following: (1) Usage of NIM media till 5 Days in vitro (DIV) for maintaining EBs and then switching them to ITSFn on sixth day, (2) addition of human stem cell factor (hSCF, Peprotech, USA) and basic fibroblast growth factor (Peprotech) in culture from DIV 7 to DIV 14 with concentrations of 50 and 25 ng/ml, respectively, (3) treatment of cultures from DIV 14 to DIV 21 with hSCF, hIL3, and human granulocyte macrophage stimulating factor (hGM-CSF, Peprotech) with concentrations of 50 ng/ml for both hSCF and hIL3, and 25 ng/ ml for hGM-CSF, and finally (4) addition of only hGM-CSF from DIV 21 onward till DIV 40 and furthermore.
immunocytochemistry/ immunofluorescence analysis
Cells from different stages of microglia induction and differentiation were fixed for performing immunocytochemistry and immunofluorescence-based analyses using primary antibodies and fluorophore-conjugated secondary antibodies. Detailed information related to fixation, antibodies, dilution, and image analysis are listed within Data sheet 1 (Supplementary Table 1 
statistical analyses
Differential expression cutoff of ±1.5 log2FC and p-value < 0.05 was considered significant unless specified. Bonferroni corrected p-value cutoff = 0.01 was applied in protein classification and pathway analyses. At least triplicate donors were considered for each developmental stage (prenatal or postnatal) for age/region analyses. In case of the in vitro experiments, we have maintained biological replicate of n = 3. resUlTs cell-Type specific gene set enrichment analysis of human Microglia
The complete GEO and SRA high-throughput databases were scanned to identify microglia-specific data sets. Out of this, two data sets were shortlisted for further in-depth in silico analyses. Initially, we analyzed the primary data set, i.e., the total gene set from the cell-type specific data comprised of significantly expressed genes in ROBC versus microglia (Figure 2A) . A total of 3,853 genes were differentially expressed, with a range comprising 6.0 log2FC as the maximum expression to −9.4 log2FC as the minimum expression. The samples of various cellular origins were tested for homogeneity via 2D-Principal Component Analysis which resulted in noticeable differences in microglia sample cluster from other cell types in Principal components, PC 1 and PC 2 ( Figure 2B ). We specifically considered the primary data set to be the cell-type data to ensure elimination of non-microglia related noise in the human brain. Furthermore, we identified known biomarkers including SPHK1, PLD4, TMEM119, and CD68, expressed in the range of 2-6 FC and used them as a positive control for in silico tracking of microglia.
Sphingosine kinase 1 is a known biomarker for quiescent neural stem cell (qNSC) pool and the key enzyme responsible for phosphorylation of sphingosine to sphingosine-1-phosphate (S1P) (38) . It has been also seen to play an important role in the regulation of proinflammatory cytokines in activated microglia (39) . Purinergic receptor 12 (P2RY12) is known to suppress microglial process motility and delay in closure of blood-brain barrier (BBB) (40) . P2RY12-mediated microglial cell activation contributes to the rapid closure of BBB small leaks, by aggregation of microglial cells at the injury site. Expression of Phos pholipase D4 (PLD4) and its localization changes are correlated with the activation state of microglia (41, 42) . This transmembrane glycoprotein localized in the endoplasmic reticulum and Golgi apparatus is primarily seen to play an important role in microglia dynamics during early postnatal brain development. Transmembrane protein 119 (TMEM119) is an established, reliable microglial marker that discriminates resident microglia from blood-derived macrophages in the human brain (43) . A glia-derived Pentraxin 3 (PTX3) expressed in the microglial secretome, has been seen to modulate phagocytic functions of microglia having crucial implications in the regulation of microglial activity in brain diseases (44) .
The secondary data set was a redundant list of total 4,776 genes which was seen to be differentially expressed among 2 human microarray data sets. This data set contains six induced microglia samples derived from human iPSCs (25) . We integrated the differentially expressed microglia-specific data enriched from both primary and secondary data sets containing 3,853 and 4,776 genes, respectively. This meta-analysis yielded a common pool of microglial specific genes (3,290) which was further used for downstream analyses (Figure 1) .
Pathway Mapping and gene set enrichment analysis
The readout of gene candidates (3,290) was used to target enriched pathways. Among the candidate pathways, GPCR, Glycerophospholipid, NOTCH1, RAP1, glycosaminoglycan metabolism, VEGFR signaling, etc. were significant ( Figure 2C ). This analysis also demonstrated enrichment of 278 out of 3,290 genes within the immune system pathway, suggesting their potential roles in microglia functioning or immune surveillance ( Figure 2C) .
The list of significantly expressed genes (3,290) was used for gene/protein type-based clustering. This analysis revealed 25 crucial protein classes that majorly comprise of 10.7% enzyme regulators, followed by 9.9% nucleic acid binding proteins, and enzymes like transferases, hydrolases, transcription factors, and signaling molecules ( Figure S1 in Supplementary Material). The other segments included cell junction, immunity/defense and extracellular matrix proteins containing 28, 40 and 46 proteins, respectively. These classes acted as guidance cues for the protein-protein based network analysis as well as pathway mapping and exposed many critical clusters of gene regulatory elements. We also performed GSEA on critically altered gene set of 20 dysregulated genes and 7 known microglia-specific markers to find critical GO terms like Immune System process, Receptor activity, Regulation of cell proliferation which further substantiated the data (Figure 2D ; Supplementary Table 2 in Supplementary Material). The aforementioned shortlisted gene set (27) was used for further analyses.
correlation analysis of Microglial Biomarkers among the Data sets
To establish correlations among the primary and secondary data sets, we calculated the Pearson correlation coefficient for the common gene pool between the two data sets (3, 290) , which resulted in a value of −0.22 (Figures 3A,B) . First, the primary and secondary datasets were analyzed for the similarity in expression of shortlisted gene set comprising 27 (20 novel + 7 known) genes ( Figure 3C ). Within the upregulated gene set, all these biomarker genes excluding GPR34 demonstrated similarity in expression when compared to the secondary data set [iPSC derived microglia (iMG) data] ( Figure 3B ). To highlight, top upregulated genes, including Dedicator of cytokinesis 2 (DOCK2), Guanylate binding protein 2 (GBP2), A disintegrin and metalloproteinase 28 (ADAM28), G Protein-coupled receptor 183 (GPR183), Calpain small subunit 2 (CAPNS2), and Fc-α receptor mediator (FCAR), were found to be consistently expressed in primary and secondary data set. Further literature mining of this top altered gene set (27) substantiated their mechanistic roles relevant to neuroinflammation and neurotoxicity. Among these, DOCK2, an atypical Rho guanine nucleotide exchange factor (GEF) for RAC and/ or CDC42 GTPases are known to regulate phagocytic activity, cytokine release, and paracrine neurotoxicity in microglia (45) . In one of the microglia-mediated neuroinflammatory cascades, the DOCK2-RAC1 pathway was seen to be elicited by S1P through an integrin-dependent association (46) . Precisely, S1P which is the phosphorylated end-product of SPHK1 is known to regulate immune cell trafficking upon binding to G-coupled receptors (GPRs) (47) . Interestingly, we found fivefold expression of a novel marker GPR183 in microglia whose role is yet to be elucidated. DOCK2 is directly regulated by the Prostaglandin E2 receptor (EP2) and has also been linked with AD pathophysiology (45) .
Concurrent evidence involving Prostaglandin signaling in microglia also suggested that balanced induction of Peroxisome proliferator-activated receptor gamma (PPARG) by LPS/IL13 or activation of EP2 can lead to neuroprotection or death of microglia via calpain-dependent pathway (48) . Our data also validated the elevated expression of PPARG as well as its downstream target calpain associated genes like CAPNS2 in the microglial pool versus the other cell types.
Another immunoeffector molecule, FCAR (CD89) was seen to be highly expressed among the top 20 altered genes in the microglial population, which also corroborated by a recent report by Galatro et al. (49) . Previous reports suggest that human microglial cells expressing truncated IRF3 show decreased expression of GBP2, thus proposing a possible link of this protein to TLR3/4-dependent neuroinflammation. Our study has shown another important marker of the microglial cell type known to be involved in CNS invasion, i.e., ADAM28, a member of the metalloproteinase family (50) . Another enriched marker gene N-acetylglucosa minyltransferase B3GNT5 was seen to be a prominent player in the expression of lactoseries sulfoglucuronylglycolipids within glycosphingolipid pathway during the prenatal brain develop-ment (51) . High expression of Kelch-like family member 6 (KLHL6) was also detected in the microglial pool, which is supported by previous AD mice model-based studies linked it to AD pathology (52). We also found an interesting factor known as macrophage scavenger receptor 1 (MSR1) invo lved in the phagocytic machinery of microglia (53) .
Contrary to this, in case of top 10 downregulated genes, the expression values for the secondary data set were found to be non-correlative to the primary data set (ROBC vs. microglia) ( Figure 3C ). Microsomal Glutathione S-Transferase 1 (MGST1), a regulator of Retinoid X receptor gamma signaling during remyelination showed non-correlative expression between the two data sets (54) . Genes like S100 Calcium Binding Protein A1 (S100A1) (55) and Gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2) (24, 56) which are known to be highly expressed in astrocytes were also seen to be enriched in the secondary data set and repressed in the primary data set, thus justifying the need to enrich a pure microglia cell type marker-enriched population for in silico and in vivo tracking. We also detected a novel gene EGF Containing Fibulin Like Extracellular Matrix Protein 1 (EFEMP1), a fibulin glycoprotein family member which was found to be downregulated in ROBC versus microglia. This was earlier shown to be upregulated in malignant gliomas and agerelated macular degeneration (57) . Another interesting observation suggested expression of several synaptosomal and synaptic receptor genes like SLC4A4 and GABRA2 significantly downregulated in the primary data set in coherence with the study by Ji et al. (58) . This analysis sheds light on probable roles of the top 20 genes in other brain cell types as well as exposes a filtered population of markers linked to microglia function in the developing human brain.
Protein-Protein interaction network analysis
To develop an in-depth understanding of the microglia-specific markers and their primary neighborhood protein partners, we constructed a primary protein-protein interaction network. Out of the input list of 3,290 genes, 994 coding proteins showed interactions with a confidence score above 0.70 (Figure 4) . Network statistical analysis showed the Network centralization score to be 0.07 and clustering coefficient to be 0.423 with a total number of hub nodes to be 43.
Subset PPI networks were constructed based on the top 20 differentially expressed gene list in combination with the known biomarkers. This network exposed primary neighborhood interacting partners of DOCK2, F3, GJA1, CHRDL1, MGST1, and ATP1A2 (Figure 4) . Among these, one of the highly upregulated genes, DOCK2 showed multiple interacting partnerships with known biomarkers like SPHK1, PTPRC, and CD68, which is substantiated by numerous connections (edges) and their respective confidence scores (Figure 4) . DOCK2 is also seen to be connected to SPHK1 through LYN, and to PTPRC, and CD68 through FYN (Figure 4) . In a second cluster, we found GJA1 to be interacting with CDH2 and TJP1. The GJA1 mutation has been seen to cause Oculodentodigital dysplasia, an autosomal dominant disorder, with high penetrance in intra-and interfamilial phenotypes (59) . In another cluster, F3 or thrombosis factor 3 was prominently associated with its own family members (Figure 4) . F3 gene encodes coagulation factor 3 which is a membrane-bound glycoprotein is part of the Tissue factor family. Although no specific links were found between F3 and brain development, it has been shown to be regulated during brain neoplasms (60) or in the innate immune cells (61, 62) . Based on GSEA, correlation, and PPI analysis, we conclude that DOCK2 acts as a molecular hub for channelized signaling in microglia-based neuroprotection, neuroinflammation, and neurological diseases, including AD and PD, Autism spectrum disorders, and schizophrenia (63) . This newly discovered microglia-specific regulator is known to be associated with disease pathology of AD patients independent of COX signaling (45) .
Trends in region-specificity for Potential, novel Microglia signatures
Cellular localization of microglia is still debatable in human brain development. Notably, the prenatal human brain displays smaller brain size with a higher number of sub-regions (26) , whereas the postnatal brain contains 18 developed sub-regions. Microglia population in the healthy brain is known to be residing primarily in hippocampus, amygdala, substantia nigra, and striatum. However, developmental tracking of human microglial activity in these regions is still elusive. To elucidate the regionspecific dynamic regulation of microglial markers, we analyzed the distribution of the identified in silico candidates. Our data revealed that in the prenatal and postnatal brain regions, the expression profiles of selected dysregulated gene set (20 + 7) was dynamically regulated as seen by their variable expression across sub-regions. Understanding this variability in their expression pattern would be crucial for building the microglial dynamic map in human brain development.
In the prenatal brain, the expression levels of known biomarker genes like PLD4, SPHK1 were high in regions of importance like caudal ganglionic eminence, medial ganglionic eminence, lateral ganglionic eminence and lower in regions like posteroinferior parietal cortex, inferolateral temporal cortex, medial frontal cortex (MFC) (Figure 5A ). However, GPCR associated genes like GPR183 and GPR34, and EFEMP1 were seen to be highly expressed only in the primary visual cortex (V1C) region in the prenatal brain ( Figure 5A ). To highlight, EFEMP1 mutations are associated with Doyne honeycomb retinal dystrophy, an autosomal dominant disorder in which there are drusen (lipid) deposits in the macula eventually leading to vision loss (64, 65) . In the postnatal brain, genes such as GBP2, astrocyte marker S100A1 and MGST1 are highly expressed in the cerebellar cortex region, while genes like GPR183, EFEMP1, and GPR34 are only expressed in MFC ( Figure 5B) . In summary, this analysis revealed consistent high expression of 14 out of 27 microglial markers in regions like hippocampus (HIP), amygdala (AMY), and striatum (STR) during postnatal development ( Figure 5B) . However, all of these 14 genes are low in expression throughout prenatal development ( Figure 5A) . Interestingly, amygdaloid complex (AMY) of the prenatal brain showed very low expression of all 27 genes, whereas the same 
Upregulated Genes in Age-Wise Distribution
In the HIP, known biomarker genes like AIF1 was found to be consistently high (log2FPKM ~ 5.0), while the expression levels of SPHK1 and GBP2 remained low (log2FPKM < 0). In STR, GBP2 was highly expressed, while AIF1 and SPHK1 were low in expression (log2FPKM < 0). In AMY, AIF1 and SPHK1 showed consistently high expression (log2FPKM ~ 3.5, 3.0), while GBP2 remained low in expression throughout prenatal to postnatal brain developmental stages (log2FPKM < 0). In case of the top upregulated genes (10), variation in gene expression was strongly evident (Figure 6 ). Among the top regulated genes, Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1), a type I integral membrane glycoprotein was found to be consistently repressed till the prenatal stages, followed by gradual increment in expression during postnatal stages (after 37 pcw) with minor inconsistencies in all the three brain regions (Figure 6) . A supporting study from mice also showed similarity in the variation of LYVE1 expression profiles in hippocampal and cerebellar regions (19) . Consistent high expression of FCAR and KLHL6 throughout pre-and postnatal development was distinct in all three aforementioned regions. The most inconsistently expressed genes across all the three regions included DOCK2 and GPR183 exhibiting a rapid decrease in expression at various ages like 12 pcw, 17 pcw, 24 pcw, 8 years, 21 years, 30 years, and 37 years suggestive of their dynamic roles in brain aging.
Downregulated Genes in Age-Wise Distribution
In case of the top downregulated gene set (10), a uniform pattern of expression was observed. In the HIP, all the genes were found to be consistently high in expression (log2FPKM ~ 4.5) throughout all the age groups excluding two inconsistently expressed genes, GJA1 and EFEMP1 (Figure 7) . We also found that EFEMP1 showed unaltered expression till the age of 19 years, followed by a sharp dip in expression at the ages of 21 and 40 years. On the other hand, GJA1 showed prominent inconsistency with a gradual decline toward 13 pcw, increase at 17 pcw, sharp dip at the age of 4 months and finally, remained unaltered in the rest of the postnatal-adult ages. In AMY, all the genes showed consistently high expression (log2FPKM ~ 4.0), which then gradually decreased toward the postnatal stages (log2FPKM ~ 3.0) excluding F3 gene. Surprisingly, expression of F3 was seen to be significantly low (log2FPKM < −2) during prenatal stages, with inconsistency in expression during postnatal ages (Figure 7) . In STR, all genes except EFEMP1, GJA1, and GABRA2 were seen to be continually expressed at a high level throughout all age groups. Especially, GABRA2 showed sharp dips at 17 pcw, 37 pcw, and 3 years whereas, GJA1 remained repressed (log2FPKM < 0) with gradual increment in expression during the postnatal stages (log2FPKM ~ 1.0) (Figure 7) . Early pieces of evidences from GJA1/Connexin 43 null and conditional knock-out mouse brains revealed its strong regulatory role in overall brain development (66) . The age-wise expression map (DDM) represented a set of gene fingerprints specific to microglia which consisted of seven genes, namely, EFEMP1, GJA1, PTX3, KLHL6, SPHK1, FCAR, and CAPNS2 ( Figure 8A ). This gene set showed consistently altered expression (both up and downregulated) in all three microglia-dense regions, across the human brain development.
To highlight, DDM also revealed three most dynamically regulated genes namely, DOCK2, LYVE1, and TMEM119 demonstrating an irregular pattern of expression across the brain ages ( Figure 8B ). These gene signatures can be further explored in vitro to elucidate their specific roles in microgliogenesis.
In Vitro Validation of Microglia-specific Biomarkers in the cellular Model of Microglia
To validate the emergence of microglia-specific biomarkers during brain development, we have established a cellular model of human microglia using an in-house standardized method.
To generate human microglial precursors in vitro, hESCs were induced for microglial commitment using a long-term culture platform, which could be maintained for a period of 4 to 6 weeks.
To authenticate the generation of microglial precursors in vitro, we have evaluated the stage-specific lineage commitment that comprised of (i) formation of EBs, (ii) neural induction, and (iii) generation of early and late microglial precursors using specific biomarkers. Details of the culture stages have been explained in the scheme (Figure 9) . Interestingly, the in silico age dyna mics study has projected SPHK1 as a key marker to be consistently upregulated at 37 pcw, specifically in AMY and HIP (Figure 6 ). It is already evident that SPHK1 plays crucial roles in microglia-dependent neuroinflammatory cascades. Additionally, we also found PTX3, which is another marker of microglia involved in regulation of phagocytic activity to be consistently downregulated across DDM of the human brain, specifically in AMY and HIP (Figure 6 ). Based on these findings, we further tried to elucidate expression of SPHK1 and PTX3 in long-term culture of human microglia. Our results have demonstrated the appearance of 3D cellular aggregates on fifth DIV with differential expression of CD24 and CD184 in both flow cytometric and confocal imaging analysis (Figure 10 ). These cellular aggregates (EBs) were further induced to form early microglial precursors as evident by expression of CD68 and AIF1/IBA1 on 21DIV as shown in the flow cytometry micrographs ( Figure 10A ). These precursors later gave rise to microglial structures on 34DIV with distinct expression of two mature microglial markers SPHK1 and PTX3, as evident in immunofluorescence-based studies ( Figure 10B ). This study has explored the optimal microenvironment for establishing cellular model mimicking human microglia and the associated important biomarkers.
DiscUssiOn
Albeit microglia constitute approximately 10% of the total cell population in the CNS (67), there are major lacunae in the knowledge regarding their expression across human brain ages and regions (68) . Many critical questions involving their ontogeny, localization, and self-renewal still need to be addressed. Discovery of novel microglial biomarkers and elucidation of their specific roles in brain developmental processes will shed light on the onset of neurological disease and progression.
Studies involving human microglia-derived transcriptomics and proteomics are still in its infancy, and given the low scope of availability of healthy/diseased human brain tissue, it is imperative to perform high-throughput data analysis to be able to identify and narrow down crucial microglia signatures (33) . In this direction, using available tissue based transcriptomics (69) as well as induced microglia microarray data generated from pluripotent stem cells (25) , we analyzed the differentially regulated gene sets pertinent to microglia biology and homeostasis, which resulted in a novel catalog of microglial biomarkers. Further using GSEA on the ascertained list, we have identified different clusters of gene sets specific to human microglia, which revealed several crucial clusters such as metalloproteinases, GPCRs, proteoglycans, immunoeffectors, gap junction family genes, and synaptosomal receptors, etc. These prominent gene clusters explained multidimensional roles and biological activity of microglia. This GSEA map acted as a primer for further downstream analyses. Correlation analysis further explained the differential expression behavior of many genes between the human brain cell types and induced microglia data sets, viz., primary and secondary data sets, respectively. Another interesting inference indicates that there might be different gene subsets required for maintaining microglial homeostasis and activity in the human brain, while enforced microglial differentiation in vitro requires an exclusive set of gene regulators. To understand the protein-protein intera ctions among the shortlisted candidates, we constructed a primary protein neighborhood network and performed pathway analysis. The study highlights some novel pathways associated with microgliasuch as Glycosaminoglycan metabolism, RAP1, Phospholipase C/D, PPAR, Fatty acid CoA signaling pathways. Upon assessment of the DDM across brain age groups, we have identified the top 20 altered genes as molecular signatures to developmentally track microglia in fetal, infant, child, adolescent, and adult brains.
Both GSEA and correlation analysis pointed out three possible hypotheses which might play roles in microglia-NPC crosstalk. The first hypothesis suggests that enhanced expression of PTGS1/2 is linked to EP2 receptors in microglia and might be the key to crosstalk with the qNSCs that express specifically PGE2. The second hypothesis discusses the interaction between microglia and qNSCs through plausible crosstalk between DOCK2 and S1P, as evidence suggests qNSCs specifically express S1P as biomarker and microglia express SPHK1, DOCK2, and S1PR1/5 (S1P receptor 1/5). The third hypothesis suggests that GPR183 acts a conditioned rheostat for NSC quiescence and activity in NOTCH1 dependent pathway. Since differential expression analysis showed high expression of GPR183 in microglia, and NOTCH1 regulates self-renewal of hippocampal NSCs, there can be possible molecular crosstalk (70, 71) .
Studies from past few decades have indicated both specific and context-dependent localization and activity of microglia during neuroinflammatory circumstances (18, 39) . However, hardly any study exists which could track their activity throughout brain development. Another major roadblock that is faced is the unavailability of human brain cells. To address such issues, we established a cellular model of the human microglial cell population and deciphered the expression of existing biomarkers, especially CD68, AIF1 (IBA1), SPHK1, and PTX3. Earlier findings have indicated that SPHK1 is found to be abundantly expressed in several rat brain cell types, including neurons in the hippocampus, cerebellar granule cells, and astrocytes and also in the amoeboid microglial cells of the corpus callosum of the postnatal brain (72) . The in silico data strongly corroborated with this existing evidence, which suggested that SPHK1 expression is significantly upregulated in microglia-dense regions, namely hippocampus and amygdala (Figure 6) . The in vitro long-term culture study also supported these findings and suggested that human microglia precursors from post 26DIV showed consistent expression of SPHK1 in late microglial precursors ( Figure 10B) . The results have also represented another unique marker, PTX3 in the in cultured human microglial precursor cells, which is known to regulate the phagocytic activity of microglia (44) . This observation supported the DDM data which has shown PTX3 to be consistently downregulated across different ages in HIP and AMY of healthy brains. In summary, our in vitro study has validated the emergence of the microglial signatures in hESC-derived human microglial precursors and also represented a robust human microglial model for future investigations involving microglial biology and activity.
Microglia has been associated with onset, aggravation, and progression of neurodegenerative diseases like Alzheimer's, Dementia, and Glioma (73) (74) (75) (76) . This is primarily due to dysregulated microglial activity during development as well as disease leading to severe neurocognitive impairments and neuronal dysfunction. Overall, this study has unraveled fundamental information underlying the labyrinthine molecular circuitry in microglia functioning, physiology, homeostasis, and genetics across brain developmental stages and regions.
cOnclUsiOn
Our study has introduced a novel integrative biology approach for tracking human microglia signatures across 25 developmental stages spanning fetal, infant, adolescence, and adult, and delineated their localized expression in microglia-dense regions. The in vitro data have also validated the expression of some of the biomarkers in human microglial precursors. Precisely, tracking of microglia transcriptomic dynamics based on brain anatomy and age could establish an essential DDM comprising highly altered gene clusters. This map can be further utilized to develop set of putative prognostic markers in accordance with the age of the human brain. One of the interesting readouts of the DDM was the dynamic expression associated with 37 pcw, i.e., a transition period between prenatal and postnatal brain. To highlight, the study has led to the discovery of microglia age-specific gene signatures, including EFEMP1, GJA1, PTX3, KLHL6, SPHK1, FCAR, and CAPNS2, which can be further explored for understanding their roles in microglial biology in the human brain.
FUTUre PersPecTiVes
In essence, this study has established a repertoire of microgliaspecific signatures involved in the developing human brain. Characterization of mechanistic roles of these gene fingerprints in experimental models would further bridge the gap in understanding the molecular mechanisms involved in microglia ontogeny, renewal, and maintenance. Age-wise expression profiling of these novel signatures (DDM) in both pre-and postnatal brain stages can act as guidance cues for designing future prognostic and diagnostic biomarkers against neurodegenerative diseases. Finally, the data associated with age and region-specificity can pave the way to personalized medicine interventions for debilitating neurological diseases.
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